Population differences in breast cancer: survey in indigenous African women reveals over-representation of triple-negative breast cancer.
OBJECTIVE
Compared with white women, black women experience a disproportionate burden of aggressive breast cancer for reasons that remain unknown and understudied. In the first study of its kind, we determined the distribution of molecular subtypes of invasive breast tumors in indigenous black women in West Africa.


METHODS
The study comprised 507 patients diagnosed with breast cancer between 1996 and 2007 at six geographic regions in Nigeria and Senegal. Formalin-fixed and paraffin-embedded sections were constructed into tissue microarrays and immunostained with 15 antibodies. Five molecular subtypes were determined, and hierarchical cluster analysis was conducted to explore subgroups for unclassified cases.


RESULTS
The mean (+/- standard deviation) age of 378 patients in the first cohort was 44.8 +/- 11.8 years, with the majority of women presenting with large (4.4 +/- 2.0 cm) high-grade tumors (83%) in advanced stages (72% node positive). The proportions of estrogen receptor (ER) -positive, progesterone receptor-positive, and human epidermal growth factor receptor 2 (HER2) -positive tumors were 24%, 20%, and 17%, respectively. Triple negativity for these markers was predominant, including basal-like (27%) and unclassified subtype (28%). Other subtypes were luminal A (27%), luminal B (2%), and HER2 positive/ER negative (15%). The findings were replicated in the second cohort of 129 patients. The unclassified cases could be grouped into a bad prognosis branch, with expression of vascular endothelial growth factor, B-cell lymphoma extra-large protein, and Cyclin E, and a good prognosis branch, with expression of B-cell lymphoma protein 2 and Cyclin D1.


CONCLUSIONS
These findings underscore the urgent need for research into the etiology and treatment of the aggressive molecular subtypes that disproportionately affect young women in the African diaspora.
Huo
Dezheng
D
Center for Clinical Cancer Genetics and Global Health, Department of Medicine, Section of Hematology/Oncology, University of Chicago, 5841 S Maryland Ave, MC 2115, Chicago, IL 60637, USA.
Ikpatt
Francis
F
Khramtsov
Andrey
A
Dangou
Jean-Marie
JM
Nanda
Rita
R
Dignam
James
J
Zhang
Bifeng
B
Grushko
Tatyana
T
Zhang
Chunling
C
Oluwasola
Olayiwola
O
Malaka
David
D
Malami
Sani
S
Odetunde
Abayomi
A
Adeoye
Adewumi O
AO
Iyare
Festus
F
Falusi
Adeyinka
A
Perou
Charles M
CM
Olopade
Olufunmilayo I
OI
D000328:Adult; D014408:Biomarkers, Tumor / Q000097:blood*; D001943:Breast Neoplasms / Q000453:epidemiology* / Q000378:metabolism*; D015331:Cohort Studies; D005260:Female; D018734:Genes, erbB-2; D006306:Health Surveys; D006801:Humans; D008875:Middle Aged; D009549:Nigeria / Q000453:epidemiology; D011960:Receptors, Estrogen / Q000097:blood*; D011980:Receptors, Progesterone / Q000097:blood*; D012675:Senegal / Q000453:epidemiology
D014408:Biomarkers, Tumor; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone
Breast Cancer Res Treat. 2008 Jul;110(1):183-8
17674190
N Engl J Med. 2006 Aug 10;355(6):560-9
16899776
Mod Pathol. 2006 Feb;19(2):264-71
16341146
Cancer. 2007 May 1;109(9):1721-8
17387718
Clin Cancer Res. 2004 Aug 15;10(16):5367-74
15328174
Breast. 2007 Dec;16 Suppl 2:S72-7
17714947
West Afr J Med. 2005 Jul-Sep;24(3):209-13
16276696
J Clin Oncol. 2006 May 10;24(14):2137-50
16682732
Cancer Res. 1990 Nov 1;50(21):7057-61
2208173
Br J Surg. 1999 May;86(5):665-8
10361191
Br J Surg. 1992 Aug;79(8):771-5
1393468
Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8
9843981
Cancer Epidemiol Biomarkers Prev. 2007 Mar;16(3):439-43
17372238
Histopathology. 1991 Nov;19(5):403-10
1757079
J Natl Cancer Inst. 2005 Mar 16;97(6):439-48
15770008
CA Cancer J Clin. 2006 May-Jun;56(3):168-83
16737949
Nat Med. 1998 Jul;4(7):844-7
9662379
Breast Cancer Res Treat. 2008 May;109(1):123-39
17578664
Cent Afr J Med. 2003 Nov-Dec;49(11-12):122-6
15301464
Nature. 2000 Aug 17;406(6797):747-52
10963602
Ann Intern Med. 2006 Apr 18;144(8):541-53
16618951
J Surg Res. 2007 Nov;143(1):109-18
17950079
Br J Cancer. 2008 Jan 29;98(2):277-81
18182985
JAMA. 1994 Sep 28;272(12):947-54
8084062
J Clin Oncol. 2006 Mar 20;24(9):1342-9
16549828
Cancer. 2007 Jan 1;109(1):25-32
17146782
JAMA. 2006 Jun 7;295(21):2492-502
16757721
Breast Cancer Res Treat. 2002 Jun;74(3):199-211
12206512